Larotrectinib Sulfate

3 trials 1 recruiting

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

1 Recruiting

2 Completed trials

3 Sponsors

10 Countries

Phase II

Phase I/II

Phase II: 2 Phase I/II: 1

Indications tested

NTRK gene fusion overexpression 2 Central nervous system neoplasm 1

Sponsors using this IMP

Bayer AG 2 Bayer Consumer Care AG 2 Nationwide Childrens Hospital 1

All trials

3 total

not applicable Recruiting

2023-508953-16-00 Phase II 1 country Nationwide Childrens Hospital
A study to test the safety and efficacy of the drug larotrectinib for the treatment of tumors with NTRK-fusion in children Ended

2022-502668-20-00 Phase I/II 9 countries Bayer AG; Bayer Consumer Care AG
"A study to learn how well the drug larotrectinib works in adults with different solid cancers with a change in the genes called NTRK fusion… Ended

2022-502667-38-00 Phase II 6 countries Bayer AG; Bayer Consumer Care AG

Showing 1–3 of 3 trials

← All drugs A–Z